Savara Begins FDA Submission for Rare Lung Disease Treatment
LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI, a potential …
Savara Begins FDA Submission for Rare Lung Disease Treatment Read More